

## PROGRESSIVE'S EVENING STROLL

DATE: 05 September, 2025

### Market Snapshot:

Once again, the Index failed to hold its gains and declined over 100 points, but a steep recovery in the mid-session helped the Index to recoup all its losses and settle the trade at 24,741 with minuscule gains of 6.70 points. The Auto and Metal segments extended their outperformance, while the IT and FMCG sectors fell by over 1%. A sharp recovery from the lower levels pushed the Mid and Small-cap segments higher, allowing them to outperform the Benchmark Index.

### HOW THE DAY TRENDED



INDICES			
Index	Close	Points	%Chg.
Sensex	80710.76	(7.25)	(0.01)
Nifty50	24741.00	6.70	0.03
Nifty Midcap 100	57075.20	116.05	0.20
Nifty Small Cap 100	17655.25	33.30	0.19

SECTORAL GAINERS / LOSERS			
Sectors	Close	Points	%Chg.
NIFTY AUTO	26320.60	325.75	1.25
NIFTY METAL	9681.65	65.30	0.68
NIFTY FMCG	56292.10	(811.95)	(1.42)
NIFTY IT	34635.85	(507.25)	(1.44)

NIFTY TOP GAINERS / LOSERS					
Gainers	CMP (Rs)	%Chg.	Losers	CMP (Rs)	%Chg.
EICHER MOTORS	6580.50	2.42	ITC	407.35	(2.06)
M&M	3561.30	2.29	HCL TECH	1419.00	(1.68)
MARUTI	14895.00	1.59	CIPLA	1553.40	(1.55)
POWER GRID	285.35	1.26	TCS	3048.30	(1.53)

### INDICES LEVELS FOR September 08, 2025

Nifty (future)	
Resistance	25000
Support	24700

Bank Nifty (future)	
Resistance	54600
Support	54000



**KEY TAKEAWAYS OF THE DAY**

◆ **Biocon Biologics' Bengaluru facility gets five observations from US FDA inspection:**

The USFDA completed a routine cGMP inspection at Biocon Biologics' drug substance facility at its Biocon Campus in Bengaluru, India. The inspection, conducted between August 26 and September 3, 2025, covered drug substance manufacturing units, analytical quality control laboratories, microbiology laboratories, and warehouses. At the conclusion of the inspection, the FDA issued a Form 483 with five observations. Biocon said these observations are procedural in nature and do not relate to data integrity, systemic non-compliance, or quality oversight.

◆ **Zydus to commercialize Synthron-supplied Ozanimod generic in US:**

The company announced that its WoS, Zydus Lifesciences Global FZE, has entered into an exclusive licensing and supply agreement with Synthron BV of the Netherlands for Ozanimod Capsules for the US market. Synthron has a pending abbreviated new drug application in the US, seeking approval for Ozanimod capsules indicated for relapsing forms of multiple sclerosis. The total addressable market opportunity in the US is approx. USD637mn as per the IQVIA MAT July 2025.

◆ **NTPC shuts down 440MW Tanda thermal plant with focus shift to renewable energy:**

The company has permanently stopped operations at the Tanda Thermal Power Station stage-I (four units of 110MW each) in Uttar Pradesh, effective September 1, 2025. Following approval and communication to the CEA, NTPC closed the facility, which trimmed the power generator's installed and commercial capacity to 82,926MW.

◆ **TVS launches NTORQ 150 scooter, 149.7cc, 0-60 km/h 6.3s, Rs119,000 ex-showroom:**

The company announced the launch of the TVS NTORQ 150, India's quickest Hyper Sport Scooter. Powered by a 149.7cc race-tuned engine and inspired by stealth aircraft design, the scooter is a symphony of high performance, sportier aesthetics and cutting-edge technology to cater to a new generation of riders, with a special introductory price of Rs119,000.

**Source: Media Reports**



## DISCLAIMERS AND DISCLOSURES-

Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products.

PSBPL is SEBI registered Research Analyst under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration No. INH000000859/Research Analyst BSE Enlistment No. 5049. PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company (s) covered in this report:-

- PSBPL or its associates financial interest in the subject company: NO
- Research Analyst (s) or his/her relative's financial interest in the subject company: NO
- PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company.
- PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO
- PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months.
- The research analyst has served as officer, director or employee of the subject company: NO
- Registration granted by SEBI and certification from NISM is in no way guarantee performance of the intermediary or provide any assurance of returns to investors

PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution publication, availability or use would be contrary to law or regulation or which would subject PSBPL or its group companies to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

## Terms & Conditions:

This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and its at discretion of the clients to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

### Registered Office Address:

Progressive Share Brokers Pvt. Ltd,  
122-124, Laxmi Plaza, Laxmi Indl Estate,  
New Link Rd, Andheri West,  
Mumbai—400053, Maharashtra  
www.progressiveshares.com | Contact No.:022-40777500.

### Compliance Officer:

Ms. Neha Oza,  
Email: compliance@progressiveshares.com,  
Contact No.:022-40777500.

### Grievance Officer:

Email: grievancecell@progressiveshares.com

